← Back to Clinical Trials
Recruiting Phase 2 NCT05446584

NCT05446584 Pathways Relating Amnestic MCI to a Mild Traumatic Brain Injury History

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05446584
Status Recruiting
Phase Phase 2
Sponsor University of Texas Southwestern Medical Center
Condition Mild Cognitive Impairment
Study Type INTERVENTIONAL
Enrollment 75 participants
Start Date 2023-04-20
Primary Completion 2027-05-01

Trial Parameters

Condition Mild Cognitive Impairment
Sponsor University of Texas Southwestern Medical Center
Study Type INTERVENTIONAL
Phase Phase 2
Enrollment 75
Sex ALL
Min Age 55 Years
Max Age N/A
Start Date 2023-04-20
Completion 2027-05-01
Interventions
High Definition Transcranial Direct Current Stimulation

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

This study will probe if the biological changes in amnestic mild cognitive impairment (aMCI) are related to a history of mild traumatic brain injury (mTBI) using high definition transcranial direct current stimulation (HD-tDCS) and blood-derived biomarker tools. Participants who Do as well as those who Do Not have a history of mTBI will be enrolled in the study.

Eligibility Criteria

Inclusion Criteria: 1. Active diagnosis of amnestic mild cognitive impairment 2. Presence of an mTBI history for the mTBI+ group; absence of an mTBI history for a control sample 3. Female and male subjects 4. All races/ethnicities 5. Age 55 years and older 6. Fluent in English Exclusion Criteria: 1. Mild traumatic brain injury within past year 2. Lifetime history of moderate or severe brain injury 3. Lifetime major neurologic syndromes (e.g., stroke, epilepsy, brain tumor) 4. Lifetime major cardiovascular conditions (e.g., heart attack, heart failure) 5. Current substance use disorder 6. Current major psychiatric disorders (e.g., major depressive disorder, bipolar disorder) 7. Current vision or hearing impairment that interferes with testing 8. Any electronic and or metallic implants in the skull or brain 9. Current medication use known to alter HD-tDCS reactivity

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology